A significant contributor to this therapeutic challenge is the overexpression of ATP-binding cassette (ABC) transporters, particularly P-gp, in AML cells, which leads to treatment resistance in approximately 40% of patients. The gene discussed is PGP; the disease is acute myeloid leukemia.